New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: A meta-analysis

Journal of the American College of Cardiology

Volumn 56, Issue 19, 2010, Pages 1542-1551

  Bellemain Appaix, Anne ^a   Brieger, David ^a   Beygui, Farzin ^a   Silvain, Johanne ^a   Pena, Ana ^a   Cayla, Guillaume ^a   Barthlmy, Olivier ^a   Collet, Jean Philippe ^a   Montalescot, Gilles ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Abbreviations and Acronyms; ACS; acute coronary syndrome(s); cardiovascular; CI; confidence interval; CV; MACE; major adverse cardiac event(s); MI; myocardial infarction; odds ratio; OR; PCI; percutaneous coronary intervention; ST; ST segment elevation myocardial infarction; STEMI; stent thrombosis; Thrombolysis In Myocardial Infarction; TIMI

Indexed keywords

ARC 669931 MX; CANGRELOR; CLOPIDOGREL; ELINOGREL; PLACEBO; PRASUGREL; PURINERGIC P2Y12 RECEPTOR BLOCKING AGENT; PURINERGIC RECEPTOR BLOCKING AGENT; TICAGRELOR; UNCLASSIFIED DRUG; DRUG DERIVATIVE; P2RY12 PROTEIN, HUMAN; PURINERGIC P2 RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; QUINAZOLINONE DERIVATIVE; SULFONAMIDE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; META ANALYSIS; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; COMPARATIVE STUDY; METABOLISM; METHODOLOGY; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, BALLOON, CORONARY; HUMANS; POSTOPERATIVE COMPLICATIONS; PURINERGIC P2 RECEPTOR ANTAGONISTS; QUINAZOLINONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, PURINERGIC P2Y12; SULFONAMIDES; TICLOPIDINE;

EID: 78049347838     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.07.012     Document Type: Article

References (33)

1. M.B. Leon, D.S. Baim, and J.J. Popma A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting Stent Anticoagulation Restenosis Study Investigators N Engl J Med 339 1998 1665 1671
2. M.E. Bertrand, H.J. Rupprecht, P. Urban, and A.H. Gershlick Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS) Circulation 102 2000 624 629
3. S.R. Steinhubl, P.B. Berger, and J.T. Mann 3rd Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial JAMA 288 2002 2411 2420
4. D.L. Bhatt, M.E. Bertrand, and P.B. Berger Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting J Am Coll Cardiol 39 2002 9 14
5. Z.M. Chen, L.X. Jiang, and Y.P. Chen Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 2005 1607 1621
6. M.S. Sabatine, C.P. Cannon, and C.M. Gibson Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study JAMA 294 2005 1224 1232
7. Mehta S. Results of the CURRENT-OASIS 7 STEMI PCI. Presented at: TCT 2009; September 24, 2009; San Francisco, CA.
8. Mehta SR. A randomized comparison of a clopidogrel high loading and maintenance dose regimen versus standard dose, and high versus low dose aspirin in 25000 patients with acute coronary syndromes: results of the CURRENT-OASIS 7 trial. Paper presented at: European Society of Cardiology 2009 Congress; August 30, 2009; Barcelona, Spain.
9. L. Wallentin, C. Varenhorst, and S. James Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease Eur Heart J 29 2008 21 30
10. P.A. Gurbel, K.P. Bliden, and K. Butler Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study Circulation 120 2009 2577 2585
11. J.S. Berger, M.T. Roe, and C.M. Gibson Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial Am Heart J 158 2009 998 1004 e1
12. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
13. D.L. Bhatt, A.M. Lincoff, and C.M. Gibson Intravenous platelet blockade with cangrelor during PCI N Engl J Med 361 2009 2330 2341
14. R.A. Harrington, G.W. Stone, and S. McNulty Platelet inhibition with cangrelor in patients undergoing PCI N Engl J Med 361 2009 2318 2329
15. S.D. Wiviott, E.M. Antman, and K.J. Winters Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial Circulation 111 2005 3366 3373
16. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
17. C.P. Cannon, S. Husted, and R.A. Harrington Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial J Am Coll Cardiol 50 2007 1844 1851
18. J.H. Chesebro, G. Knatterud, and R. Roberts Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase Clinical findings through hospital discharge Circulation 76 1987 142 154
19. S.D. Wiviott, D. Trenk, and A.L. Frelinger Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial Circulation 116 2007 2923 2932
20. M. Cucherat, J.P. Boissel, A. Leizorovicz, and M.C. Haugh EasyMA: a program for the meta-analysis of clinical trials Comput Methods Programs Biomed 53 1997 187 190 (Pubitemid 27305437)
21. M. Clarke, and A.D. Oxman Cochrane reviewer's handbook 4.2.0 issue update software 2003 Cochrane Collaboration Oxford
22. S.D. Wiviott, E. Braunwald, and C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
23. Steg G, James S, Harrington R, et al. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes: the PLATelet Inhibition and patient Outcomes trial: outcomes in patients with STEMI and planned PCI. Presented at: American Heart Association 2009; November 1418, 2009; Orlando, FL
24. C.P. Cannon, R.A. Harrington, and S. James Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study Lancet 375 2010 283 293
25. G. Montalescot, S.D. Wiviott, and E. Braunwald Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet 373 2009 723 731
26. L. Bonello, L. Camoin-Jau, and S. Armero Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis Am J Cardiol 103 2009 5 10
27. L. Bonello, L. Camoin-Jau, and S. Arques Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol 51 2008 1404 1411
28. G. Montalescot, G. Sideris, and C. Meuleman A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial J Am Coll Cardiol 48 2006 931 938
29. A. Bellemain-Appaix, G. Montalescot, and J. Silvain Slow response to clopidogrel predicts low response J Am Coll Cardiol 55 2010 815 822
30. J.P. Collet, J.S. Hulot, and A. Pena Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
31. T. Simon, C. Verstuyft, and M. Mary-Krause Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
32. A.R. Shuldiner, J.R. O'Connell, and K.P. Bliden Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
33. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362